Innate Pharma Announces Its Participation in Upcoming Investor Conferences
Innate Pharma S.A. - American Depositary Shares (IPHA)
Company Research
Source: Business Wire
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced members of its executive team are scheduled to participate in the upcoming conferences, detailed below. Participants will include Hervé Brailly, Chief Executive Officer, Sonia Quaratino, Executive Vice President (EVP), Chief Medical Officer, Yannis Morel, EVP, Chief Operating Officer and Arvind Sood, EVP, President of US Operations.Jefferies Global Healthcare ConferenceEvent dates: June 5-6, 2024 | New York, United StatesGoldman Sachs 45th Annual Global Healthcare ConferenceEvent dates: June 10-13, 2024 | Miami, United StatesH.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceEvent date: June 25, 2024 | VirtualStifel 2nd European Healthcare Summit LyonEvent dates: June 25-27, 2024 | Lyon, FranceAbout Innate PharmaInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer pat
Show less
Read more
Impact Snapshot
Event Time:
IPHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPHA alerts
High impacting Innate Pharma S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IPHA
News
- Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024Business Wire
- Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 TrialBusiness Wire
- Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.MarketBeat
- Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides [Yahoo! Finance]Yahoo! Finance
- Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis FungoidesBusiness Wire